



Mithra Announces Publication of Estelle® Abstracts in Connection with the 13th Annual Meeting of the European Society of Gynecology

Liege, Belgium, 22 October 2019 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces the publication of abstracts on Estelle® clinical results presented at the 13th Annual Meeting of the European Society of Gynecology (ESG) held from 16-19 October 2019 in Vienna, Austria.

More than 400 gynaecologists, doctors and researchers participated in the opening symposium entitled "*Estetrol: 4 reasons to believe in a new era in oral contraception*". Based on a survey conducted at the end of the session, nearly 90% of the experts believe that the choice of estrogen in a combined oral contraceptive (COC) is essential. Even more acknowledge that Estelle®, Mithra's novel COC product candidate based on Estetrol (E4) 15 mg and drospirenone (DRSP) 3 mg, shows promising clinical results.

Prof. Andréa Genazzani, President of the European Society of Gynecology, commented: "*Clinical results are excellent and were eagerly awaited by the scientific community here in Vienna. Estetrol is a major innovation that meets women's needs in terms of convenience, while offering an improved benefit-risk profile.*"

Dr Céline Bouchard, FRCSC Women’s Health Clinic, Québec, Canada, commented: "*I have been involved in many clinical research projects in contraception. The combination of E4/DRSP is different and should revolutionize contraception because E4 has a very favorable metabolic and hemostatic profile. E4/DRSP promises to be a "game changer" with an estrogen more in line with women's needs.*"

Mithra’s participation to the ESG equally served as an opportunity to meet our worldwide partners for Estelle® to discuss the global commercialization strategy. This is the second global partnership meeting since September, and illustrates the commitment of Mithra and its partners to making Estelle® a success.

The presentations are available in the [investors section](#) of the company’s website:

- "*Estetrol 15 mg combined with drospirenone 3 mg is an effective oral contraceptive: results from the E4Freedom EU/RU phase 3 trial*" - Abstract Id 9027;
- "*Excellent cycle control of an estetrol 15 mg and drospirenone 3 mg combined oral contraceptive in the E4Freedom EU/RU phase 3 trial*" - Abstract Id 9030;
- "*Contraceptive Efficacy and Bleeding Pattern of a New COC containing Estetrol 15 mg and drospirenone 3 mg - Phase 3 Trial Results*" – Abstract Id 8840;
- "*E4Relief: a phase 2b study with Estetrol (E4), the next generation hormone therapy for menopausal symptoms*" - Abstracts Id 9049.

For more information, please contact:

Alexandra Deschner (IRO) : +32 490 58 35 23 - investorrelations@mithra.com

Maud Vanderthommen (Press) : +32 473 58 61 04 – press@mithra.com

About Mithra

Mithra (Euronext: MITRA) is dedicated to providing innovation and choice in Women's Health, with a particular focus on contraception and menopause. Mithra's goal is to develop new and improved products that meet women's needs for better safety and convenience. Its three lead development candidates – a fifth generation oral contraceptive Estelle®, the first complete oral treatment for perimenopause PeriNesta™ and next-generation hormone therapy Donesta® - are built on Mithra's unique native estrogen platform, E4 (Esetrol). Mithra also develops and manufactures complex therapeutics and offers partners a complete spectrum of research, development and specialist manufacturing at its CDMO. Mithra was founded in 1999 as a spin-off from the University of Liège by François Fornieri and Prof. Dr. Jean-Michel Foidart. Mithra is headquartered in Liège, Belgium. Further information can be found at www.mithra.com

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

To receive our press releases by email, please subscribe to our mailing list on investors.mithra.com